Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Pelle L. Ishøy"'
1
Akademický článek
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Autor: Robert Eriksson, Brian V. Broberg, Pelle L. Ishøy, Nikolaj Bak, Ulrik B. Andersen, Niklas R. Jørgensen, Filip K. Knop, Bjørn H. Ebdrup
Publikováno v: Frontiers in Psychiatry, Vol 9 (2019)
Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also a
Externí odkaz: https://doaj.org/article/96668b960e5b4b0eb02e97e74946f9ca
Zobrazit plný text záznamu
2
No cognitive‐enhancing effect of GLP ‐1 receptor agonism in antipsychotic‐treated, obese patients with schizophrenia
Autor: Nikolaj Bak, Filip K. Knop, Birgitte Fagerlund, Birte Glenthøj, Pelle L. Ishøy, Brian V. Broberg, Bjørn H Ebdrup
Publikováno v: Acta Psychiatrica Scandinavica. 136:52-62
Objective Schizophrenia is associated with profound cognitive and psychosocial impairments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for diabetes and obesity treatment, and animal studies have indicated cognitive-enhancing effect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::07e205712c2fc008997720b9f2af7f2a
https://doi.org/10.1111/acps.12711
Zobrazit plný text záznamu
3
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis
Autor: Steve Kisely, Pelle L. Ishøy, Dan Siskind, Tina Vilsbøll, Anders Fink-Jensen, Margaret Hahn, Christoph U. Correll, Bjørn H Ebdrup, Brian V. Broberg, Nikolaj Bak, Anthony W. Russell, Julie M. Larsen, Filip K. Knop
Publikováno v: Diabetes, obesitymetabolism. 21(2)
To evaluate if glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce antipsychotic-associated body weight gain in patients with schizophrenia, when compared to controls.We systematically searched PubMed/EMBASE/PsycINFO/Cochrane using the search
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a199bb150e33d9f40326842c0cb01f8
https://pubmed.ncbi.nlm.nih.gov/30187620
Zobrazit plný text záznamu
4
O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS
Autor: Niklas Rye Jørgensen, Bjørn H Ebdrup, Pelle L. Ishøy, Nikolaj Bak, Brian V. Broberg, Ulrik B. Andersen, Robert Eriksson, Filip K. Knop
Publikováno v: Schizophrenia Bulletin. 45:S198-S199
BACKGROUND: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091265cd114bded3c3568ab59063e808
https://doi.org/10.1093/schbul/sbz021.268
Zobrazit plný text záznamu
6
Erratum: Effect of GLP ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: A randomized, placebo‐controlled trial
Autor: Pelle L. Ishøy, Nikolaj Bak, Ulrik B. Andersen, Niklas Rye Jørgensen, Brian V. Broberg, Filip K. Knop, Jens J. Holst, Birte Glenthøj, Bjørn H Ebdrup
Publikováno v: Diabetes, Obesity & Metabolism
BASE-Bielefeld Academic Search Engine
Ebdrup, B H, Broberg, B V, Ishøy, P L, Bak, N, Andersen, U B, Jørgensen, N R, Holst, J J, Knop, F K & Glenthøj, B Y 2018, ' Erratum to : Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial ', Diabetes, Obesity and Metabolism, vol. 20, no. 5, pp. 1327-1328 . https://doi.org/10.1111/dom.13204
Aims Schizophrenia is associated with cardiovascular co-morbidity and a reduced life-expectancy of up to 20 years. Antipsychotics are dopamine D2 receptor antagonists and the standard of medical care in schizophrenia, but the drugs are associated wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00bebe8380cf640fabad5e9d9895710b
https://doi.org/10.1111/dom.13204
Zobrazit plný text záznamu
7
SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity
Autor: Niklas Rye Jørgensen, Birgitte Fagerlund, Filip K. Knop, Brian V. Broberg, Ulrik B. Andersen, Bjørn H Ebdrup, Nikolaj Bak, Jens J. Holst, Pelle L. Ishøy, Birte Glenthøj
Publikováno v: Schizophrenia Bulletin. 43:S167-S167
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes, and we investigated metabolic and cognitive effects of the GLP-1RA, exenatide once weekly, in nondiabetic, antipsychoti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae154519f6cbc2d29554524340eb3449
https://doi.org/10.1093/schbul/sbx024.017
Zobrazit plný text záznamu
8
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
Autor: Egill Rostrup, Pelle L. Ishøy, Bjørn H Ebdrup, Henrik Lublin, Birte Glenthøj, Birgitte Fagerlund, Filip K. Knop
Publikováno v: BMC Medicine, Vol 10, Iss 1, p 92 (2012)
BASE-Bielefeld Academic Search Engine
BMC Medicine
Background Antipsychotic-induced weight gain constitutes a major unresolved clinical problem which may ultimately be associated with reducing life expectancy by 25 years. Overweight is associated with brain deterioration, cognitive decline and poor q
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a5cd1585dded82db5107791b909c11
http://www.biomedcentral.com/1741-7015/10/92
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje